{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:02:25Z","timestamp":1791345745858,"version":"4.3.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.autrev.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T06:39:25Z","timestamp":1523083165000},"page":"610-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"17","author":[{"given":"Milena","family":"Tocut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Zandman-Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.01.010_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy\u2014 implications for rheumatology","volume":"43","author":"Cappelli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.autrev.2018.01.010_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"10","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.autrev.2018.01.010_bb0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0020","first-page":"8","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0025","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"1","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2018.01.010_bb0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.autrev.2018.01.010_bb0040","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0045","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"29","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.01.010_bb0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2018.01.010_bb0055","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clinthera.2015.02.003","article-title":"Cytotoxic T-lymphocyte antigen-4 blockade in melanoma","volume":"37","author":"Buchbinder","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2018.01.010_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2018.01.010_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.010_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MCP.0000000000000382","article-title":"Pneumotoxicity associated with immune checkpoint inhibitor therapies","volume":"23","author":"Shannon","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Caner Res"},{"key":"10.1016\/j.autrev.2018.01.010_bb0090","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0095","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0100","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2018.01.010_bb0105","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0110","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.01.010_bb0115","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.autrev.2018.01.010_bb0125","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.010_bb0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0135","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.39406","article-title":"Auto-immune arthropathy and uveitis as complications from PD-1 inhibitor","volume":"68","author":"De Velasco","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.010_bb0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ccr3.911","article-title":"Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma","author":"Matsuo","year":"2017","journal-title":"Clin Case Rep."},{"key":"10.1016\/j.autrev.2018.01.010_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0150","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12991","article-title":"Case of respiratory discomfort due to myositis after administration of nivolumab","volume":"42","author":"Yoshioka","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.autrev.2018.01.010_bb0160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathtoxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2018.01.010_bb0165","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.010_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-014-0041-1","article-title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","volume":"2","author":"Manusow","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2018.01.010_bb0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.47.5095","article-title":"Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab","volume":"31","author":"Minor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus. nephritis.nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and pPreexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0200","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5301\/ejo.5000724","article-title":"A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab","volume":"26","author":"Abu Samra","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0205","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1078155211411001","article-title":"Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma","volume":"18","author":"Ahmad","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.autrev.2018.01.010_bb0210","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","article-title":"Neutropenia in a patient treated with ipilimumab (anti-CTLA-4Antibody)","volume":"32","author":"Akhtari","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2018.01.010_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2018.01.010_bb0220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/kes189","article-title":"Malignancy as a comorbidity in rheumatic diseases","volume":"52","author":"Turesson","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.010_bb0225","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's granulomatosis etanercept trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.010_bb0230","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","article-title":"Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab","volume":"54","author":"Johnston","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2018.01.010_bb0235","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0240","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2018.01.010_bb0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1568-9972(02)00086-1","article-title":"HIV and autoimmunity","volume":"1","author":"Zandman-Goddard","year":"2002","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.010_bb0250","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.autrev.2014.04.005","article-title":"Autoimmune diseases in HIV-infected patients: 52 cases and literature review","volume":"13","author":"Iordache","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.010_bb0255","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.med.53.082901.104032","article-title":"Immune reconstitution in patients with HIV infection","volume":"53","author":"Sempowski","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0260","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.autrev.2014.04.005","article-title":"Autoimmune diseases in HIV-infected patients: 52 cases and literature review","volume":"13","author":"Iordache","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.010_bb0265","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1086\/317422","article-title":"Sarcoidosis after antiretroviral therapy in a patient with acquired immunodeficiency syndrome","volume":"31","author":"Gomez","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2018.01.010_bb0270","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.119.3.978","article-title":"Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy","volume":"119","author":"Lenner","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2018.01.010_bb0275","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1164\/ajrccm.159.6.9807152","article-title":"Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy","volume":"159","author":"Naccache","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2018.01.010_bb0280","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.md.0000159082.45703.90","article-title":"Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease","volume":"84","author":"Chen","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.01.010_bb0285","first-page":"4254","article-title":"Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients","volume":"85","author":"Jubault","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2018.01.010_bb0290","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(05)60398-4","article-title":"Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy","volume":"352","author":"Gilquin","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.01.010_bb0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12026-016-8811-0","article-title":"Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome)","volume":"65","author":"Jara","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2018.01.010_bb0300","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203316686406","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome) - an update","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.010_bb0305","first-page":"1","article-title":"The autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)\/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry","volume":"25","author":"Watad","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.010_bb0310","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.autrev.2015.05.014","article-title":"On vaccine's adjuvants and autoimmunity: current evidence and future perspectives","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.010_bb0315","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.autrev.2011.10.015","article-title":"Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment","volume":"11","author":"Bijl","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.010_bb0320","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T08:01:45Z","timestamp":1604131305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218300892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1568997218300892"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.010","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}